Maspero Marianna, Pezzoli Isabella, Di Guardo Lorenza, Angi Martina, Lo Dico Silvia, Sposito Carlo, Battiston Carlo, Mazzaferro Vincenzo
HPB Surgery, Hepatology and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Ann Surg Oncol. 2025 Jul;32(7):4989-4996. doi: 10.1245/s10434-025-17115-0. Epub 2025 Apr 17.
Uveal melanoma metastasizes to the liver in almost 50% of patients. The prognosis of liver metastases from uveal melanoma (LMUM) is dismal; however, results from retrospective monocentric series suggest that surgery may improve survival in selected patients. We report our results of surgical explorations and hepatic resections for LMUM.
We retrospectively analyzed our prospectively collected institutional database of hepatic resections for LMUM between 2013 and 2023.
In total, 22 patients underwent surgical exploration (median age 61 years, 41% female patients): 15 (68%) underwent curative-intent surgery (surgery group) while 7 (32%) had their resection aborted owing to intraoperatively unresectable disease (staging alone group). Patients in the surgery group had a longer interval between diagnosis of the primary tumor and LMUM (> 36 months in 64%, versus 29% in the staging alone group, p = 0.18). Preoperative imaging and intraoperative staging were concordant in ten (45%) cases, while five (23%) had more lesions, six (27%) had miliary disease, and one (4.5%) had peritoneal carcinomatosis. Minor postoperative complications occurred in 3 (14%) patients. All patients in the staging alone group underwent subsequent systemic or locoregional treatment. Median overall survival was 27 (15-47) months after surgery and 15 (8-21) months after staging alone. Recurrence after surgery occurred in 7/15 patients, with a median disease-free survival of 28 (4-38) months.
More than 30% of patients with LMUM with preoperatively resectable disease are unresectable at explorative surgery. Acceptable recurrence rates and good survival outcomes are observed when radical surgery can be performed.
近50%的葡萄膜黑色素瘤患者会发生肝转移。葡萄膜黑色素瘤肝转移(LMUM)的预后很差;然而,回顾性单中心系列研究结果表明,手术可能会改善部分患者的生存率。我们报告了我们对LMUM进行手术探查和肝切除的结果。
我们回顾性分析了2013年至2023年间前瞻性收集的LMUM肝切除机构数据库。
共有22例患者接受了手术探查(中位年龄61岁,41%为女性患者):15例(68%)接受了根治性手术(手术组),而7例(32%)因术中无法切除的疾病而中止了切除(仅分期组)。手术组患者从原发性肿瘤诊断到LMUM的间隔时间更长(64%超过36个月,而仅分期组为29%,p = 0.18)。术前影像学检查和术中分期在10例(45%)病例中一致,而5例(23%)有更多病灶,6例(27%)有粟粒性疾病,1例(4.5%)有腹膜癌转移。3例(14%)患者出现轻微术后并发症。仅分期组的所有患者均接受了后续的全身或局部治疗。手术后的中位总生存期为27(15 - 47)个月,仅分期后的中位总生存期为15(8 - 21)个月。15例患者中有7例术后复发,无病生存期的中位时间为28(4 - 38)个月。
超过30%术前可切除疾病的LMUM患者在探查手术中无法切除。当能够进行根治性手术时,可观察到可接受的复发率和良好的生存结果。